Latest news

• US pauses shipments of Eli Lilly’s COVID-19 antibody treatment due to variant concerns

  The US Department of Health and Human Services (HHS) decided to halt shipments of the antibody cocktail – comprised of bamlanivimab and etesevimab – after laboratory analyses found the therapy was not effective ... In April, the US Food and Drug

• Eli Lilly/AbCellera’s COVID-19 variant-targeting antibody enters clinical trials

  However, a combination of bamlanivimab and etesevimab still retains an EUA for the treatment of mild-to-moderate COVID-19 in high-risk adults and paediatric patients aged 12 years and

• Lilly cuts 2021 guidance to reflect ‘lower expected revenue’ from COVID-19 antibody sales

  Based on the rollout of the vaccine across major markets, current antibody utilisation rate, existing US government bamlanivimab supply and the transition to only supply bamlanivimab and etesevimab administered together in

• Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US

  Following this, Lilly advanced the further development of bamlanivimab plus another of its neutralising mAbs – etesevimab – to be administered together. ... This represented a 70% risk reduction, with no deaths occurring in the bamlanivimab and

• Lilly, Vir and GSK’s antibodies reduce viral load by 70% in low-risk COVID-19 patients

  deaths in high-risk COVID-19 patients when combined with its other antibody etesevimab.